Inactive Instrument

Other languages Edge Therapeutics Inc Nasdaq

Equities

US2798701098

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Empire Metals targets key milestones in Australia	Mar. 27
PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
PDS Biotechnology Corporation Announces Publication of Preclinical Research	Mar. 13
PDS Biotechnology Corporation Announces Executive Changes	Jan. 22
Apyx Medical Names Matthew Hill as CFO	Nov. 28
PDS Biotechnology Appoints Lars Boesgaard as Finance Chief	Nov. 28
PDS Biotechnology Corporation Announces Resignation of Matthew Hill as Principal Financial Officer and Principal Accounting Officer, Effective December 1, 2023	Nov. 28
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
NetScientific's portfolio company updates on cancer trial	Nov. 09
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients	Nov. 09
NetScientific investee claims promising results in biomarker study	23-10-23
PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO	23-10-23
PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer	23-10-11
NetScientific portfolio company updates on cancer trial	23-10-03
PDS Biotechnology Corporation Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA	23-10-03
PDS Biotechnology Investigational Vaccine Shows 'Active Neutralization' of Multiple Influenza Viruses in Preclinical Studies	23-09-20
PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies	23-09-20
NetScientific's PDS suffers wider loss as R&D costs mount	23-08-14
PDS Biotechnology Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial	23-08-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Edge Therapeutics Inc Nasdaq

Equities

US2798701098

Other languages

Filters